Managing Neutropenia in Older Patients With Cancer Receiving Chemotherapy in a Community Setting
Authors:
- Irene Q. FloresIFIrene Q. Flores
- William ErshlerWEWilliam Ershler
- 1 January 2010
- journal article
- research article
- Published by Oncology Nursing Society (ONS) in Clinical Journal of Oncology Nursing
- Vol. 14 (1) , 81-86
Abstract
Older patients with cancer who may be more susceptible than younger patients to the myelosuppressive effects of chemotherapy undergo dose delays and reductions that can compromise treatment outcomes. Incidence of neutropenic complications and suboptimal chemotherapy delivery can be reduced with prophylactic colony-stimulating factors; however, their use in older patients with cancer has not been well studied. A randomized, multicenter, community-based trial was designed to compare prophylactic pegfilgrastim use (all cycles of chemotherapy) versus its more common reactive use (at clinicians' discretion) in patients aged 65 years or older with various cancers. Pegfilgrastim use in all cycles reduced the incidence of febrile neutropenia by about 60% and hospitalizations caused by neutropenia and febrile neutropenia by about 50% versus reactive pegfilgrastim use in later cycles. The study showed that older patients with cancer can be treated safely with optimal doses of chemotherapy with appropriate supportive care. Nurses, key collaborators in providing supportive care, can take an active role in identifying older patients who may benefit from pegfilgrastim in all cycles of chemotherapy.Keywords
This publication has 38 references indexed in Scilit:
- Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle PegfilgrastimThe Oncologist, 2007
- Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trialCritical Reviews in Oncology/Hematology, 2007
- Nurses' Guide to Understanding and Implementing the National Comprehensive Cancer Network Guidelines for Myeloid Growth FactorsOncology Nursing Forum, 2007
- EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEuropean Journal of Cancer, 2006
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Development and Implementation of a Risk Assessment Tool for Chemotherapy-Induced NeutropeniaOncology Nursing Forum, 2006
- Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapyCancer, 2005
- Never Too Old? Age Should Not Be a Barrier to Enrollment in Cancer Clinical TrialsThe Oncologist, 2005
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995